anc-501
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2022 (NCT05439603)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vasopressin V1b receptorANTAGONIST
AVPR1B antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)NC(=O)Cn1c(-c2cccc(Cl)c2)nn(-c2ccc(CCN3CCOCC3)cc2)c1=O- Mol. weight
- 484 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314910 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05439603 | Phase 2 | Sep 19, 2022 | Ancora Health |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ancora Health | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1